Join Growin Stock Community!

台睿6580.TW Overview

TW StockBiotech. & Medical
(No presentation for 6580)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

台睿（6580）Overall Performance

台睿（6580）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

台睿（6580） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

台睿（6580）Key Information

台睿（6580）Profile

TaiRx, Inc., a pharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cancer and other diseases. The company's products under development include CVM-1118, an oral anti-cancer drug that is Phase II clinical trial; and Rexis, an add-on injection therapy that is in Phase III clinical trials to treat patients with sepsis. Its pre-clinical products comprise TRX-711 that is used to treat secondary hyperparathyroidism; TRX-920, an oral delivery formulation; and TRX-105, a molecule developed for treating and alleviating symptoms of various colitis. The company also offers Zelnite, a drug that helps in patient's blood Se level and immune system; and focuses on development of the nodal diagnostic devices and anti-body drugs. TaiRx, Inc. was founded in 2011 and is based in Taipei City, Taiwan.

台睿（6580）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.91
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
101.58
PB Ratio
3.66
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
22.33%
Net Margin
-1567.56%
Revenue Growth (YoY)
71.87%
Profit Growth (YoY)
-27.76%
3-Year Revenue Growth
74.36%
3-Year Profit Growth
45.59%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.91
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
101.58
PB Ratio
3.66
Price-to-FCF
-
Gross Margin
22.33%
Net Margin
-1567.56%
Revenue Growth (YoY)
71.87%
Profit Growth (YoY)
-27.76%
3-Year Revenue Growth
74.36%
3-Year Profit Growth
45.59%
default symbol

6580

台睿

18.85D

-1.06%

(-0.01)

  • When is 6580's latest earnings report released?

    The most recent financial report for 台睿 (6580) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6580's short-term business performance and financial health. For the latest updates on 6580's earnings releases, visit this page regularly.

  • What is the operating profit of 6580?

    According to the latest financial report, 台睿 (6580) reported an Operating Profit of -79.21M with an Operating Margin of -1,055.58% this period, representing a decline of 4.97% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 6580's revenue growth?

    In the latest financial report, 台睿 (6580) announced revenue of 7.5M, with a Year-Over-Year growth rate of 2,731.7%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 6580 have?

    At the end of the period, 台睿 (6580) held Total Cash and Cash Equivalents of 131.27M, accounting for 0.22 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 6580 go with three margins increasing?

    In the latest report, 台睿 (6580) did not achieve the “three margins increasing” benchmark, with a gross margin of 11.77%%, operating margin of -1,055.58%%, and net margin of -999.33%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6580's profit trajectory and future growth potential.

  • Is 6580's EPS continuing to grow?

    According to the past four quarterly reports, 台睿 (6580)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.68. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 6580?

    台睿 (6580)'s Free Cash Flow (FCF) for the period is -1.62M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 80.91% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.